This guide links the evidence behind the localized and binding-class assertions. The preserved source-evidence record retains the detailed source boundaries, and the reproducible source audit derives interaction identities, propagation, per-location HPA confidence and product distinctions from saved inputs. This guide is a locator and synthesis, not a separate biological experiment.
Lu et al., PMID:28530676 reports endogenous DZIP1L staining with two antibodies. The Results describing Figure 4j–k distinguish human dermal-fibroblast colocalization with TCTN1 from human RPE-1 3D-SIM showing nearby DZIP1L/TCTN1 signals. The immunofluorescence Methods specify the antibodies, fixation and structured-illumination acquisition. This supports GO:0035869 ciliary transition zone, in addition to independently retained centriole and basal-body locations. The reported approximately 120-nm lateral resolution is not a molecular contact measurement, an exclusive-residence claim or a purified gate-complex assay. The text and Methods were read; no new figure-pixel inspection is claimed.
The current transition-zone definition and typed ancestry distinguish it from centriole and ciliary basal body. One authored IDA/located_in row captures this measured target location. No new biological-process term follows from the definition's discussion of gating. The same study's human families and official DZIP1L disease record support autosomal-recessive polycystic kidney disease 5 context.
Glazer et al., PMID:19852954 independently supports tagged human DZIP1L at the ciliary base and the combined DZIP1/DZIP1L depletion phenotype. The archived human IMAGE4940443 clone has the long-product architecture but three differences from the current displayed sequence. Wang et al., PMID:29487109 uses mouse Dzip1l constructs and mutant cells to examine Cby positioning and ciliary-bud formation. These source-specific results do not imply that every human product or every cell type has identical behavior.
GO:0008092 covers binding to a cytoskeletal protein component. The microtubule-cytoskeleton definition includes associated proteins. Thus a documented centrosomal or centriolar component can qualify without itself polymerizing into a filament; mere transient localization would not establish that class. GO:0097110 identifies binding to a signaling scaffold. These are partner-class terms, not assertions that DZIP1L performs the partner's activity.
| Partner / existing zero-based rows | Independent class evidence | Exact association scope |
|---|---|---|
| CEP76, Q8TAP6 / 1, 4, 5 | Official CEP76 identifies a centrosomal component regulating centriole duplication and associating with CCP110/CEP97, with experimental provenance to PMID:19460342(https://pubmed.ncbi.nlm.nih.gov/19460342/) and PMID:14654843(https://pubmed.ncbi.nlm.nih.gov/14654843/). Those partner papers are cited through the curated authority; no new full-body read is claimed. | Human positive two-hybrid records IM-23318-38646, IM-27553-525 and IM-27438-30. The no-effect mutation features in the latter two belong to DZIP1L, not CEP76, and do not denote loss of binding. |
| CBY1, Q9Y3M2 / 13, 14 | Official CBY1 records human centriolar/basal-body localization and FAM92A recruitment associations. The separately read mouse study PMID:29487109 identifies Cby as a mother-centriolar appendage component. | HuRI IM-25472-129202 is a positive validated human binary record. BioPlex IM-29278-14305 is tagged CBY1 bait with DZIP1L prey in anti-tag co-IP/AP-MS and spoke expansion. Independent binary corroboration does not convert the AP-MS experiment into purified direct binding. |
| AMOTL2, Q9Y2J4 / 12 | Official AMOTL2 documents human WWP1/Crumbs, LATS2 and YAP-pathway coordination. Its MAGI1/CDH5 scaffold account is separately by similarity and is not the sole class evidence. | Human HuRI IM-25472-114743 is positive in validated two-hybrid; the sufficient-binding region is AMOTL2 residues 314–779. Partner identity does not establish autonomous scaffold activity of this fragment or DZIP1L Hippo-pathway regulation. |
The source studies are HI-II-14, PMID:25416956, variant framework, PMID:29892012, variant screen, PMID:31515488, HuRI, PMID:32296183, and BioPlex, PMID:33961781. Stable interaction identifiers, complete literal fields and reference-sequence ROGID joins are retained in the published audit. A matching reference-sequence ROGID is not a claim that every historical plasmid insert was independently resequenced. Orthogonal validation is asserted only where the actual target record supports it.
The PMID:29892012 machine cache marks full text available but contains only partial article text, omitting operative Methods/Results. A separately attempted PMC representation is a challenge page and was excluded. The review therefore keeps its explicit incomplete-access flag and makes no mutation-mechanism claim from that missing text. The positive human DZIP1L–CEP76 record is independently checked in IntAct, with corroborating positive pairs in PMID:25416956 and PMID:31515488 and a separately established CEP76 class. This is sufficient for the bounded class-binding assertion; citation correctness and availability remain separate assessments. Genuine cache bytes and flags are preserved.
The HPA target page supports basal body at the individual-location level. Its additional cytosol observation is Uncertain, as are its other secondary locations in the saved capture. The broad PAINT cytoplasm assertion is refined biologically using positive human centriolar/basal-body evidence, without claiming a formal cytoplasm ancestry edge or exhaustive coverage of all target molecules.
The seven supported generic-binding rows follow the explicit ClinGen project instruction, lines 2976–2978. A supported positive association stays non-core where no evidence-backed narrower class is established. More informative supported classes are retained as MODIFY, and unadjudicable evidence would require UNDECIDED. Generic-binding advisories do not establish source falsity or override this task-specific instruction.
All 28 imported source objects, their existing actions, two official products, source archives and prior analysis remain intact. The follow-up adds one measured location and no new quotation, process assertion or independent scaffold activity.